401 Aufrufe 401 0 Kommentare 0 Kommentare

    FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit!

    New York, New York--(Newsfile Corp. - September 7, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA) and certain of its officers.

    Class Definition

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Moderna Inc!
    Long
    57,69€
    Basispreis
    0,32
    Ask
    × 14,20
    Hebel
    Short
    64,74€
    Basispreis
    0,50
    Ask
    × 12,88
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MRNA.

    Case Details

    The Compliant alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) mRNA-1345 was less effective than Defendants had led investors to believe; (2) accordingly, mRNA-1345's clinical and/or commercial prospects were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

    What's Next?

    A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MRNA or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Moderna you have until October 8, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

    There is No Cost to You

    We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

    Why Bronstein, Gewirtz & Grossman

    Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contact

    Bronstein, Gewirtz & Grossman, LLC
    Peretz Bronstein or Nathan Miller
    332-239-2660 | info@bgandg.com

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219656


    The Moderna Stock at the time of publication of the news with a raise of +0,09 % to 65,45USD on Lang & Schwarz stock exchange (07. September 2024, 13:00 Uhr).

    Diskutieren Sie über die enthaltenen Werte


    newsfile
    0 Follower
    Autor folgen

    Verfasst von newsfile
    FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit! New York, New York--(Newsfile Corp. - September 7, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") …